Weaver Capital Management LLC raised its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 30.9% during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 12,261 shares of the company's stock after buying an additional 2,891 shares during the quarter. Weaver Capital Management LLC's holdings in Johnson & Johnson were worth $2,033,000 at the end of the most recent quarter.
Other institutional investors also recently added to or reduced their stakes in the company. Monte Financial Group LLC raised its stake in shares of Johnson & Johnson by 1.3% in the first quarter. Monte Financial Group LLC now owns 36,636 shares of the company's stock valued at $5,769,000 after purchasing an additional 464 shares in the last quarter. CCG Wealth Management LLC acquired a new position in shares of Johnson & Johnson in the 1st quarter valued at $252,000. Marietta Wealth Management LLC lifted its holdings in shares of Johnson & Johnson by 2.0% during the 1st quarter. Marietta Wealth Management LLC now owns 32,375 shares of the company's stock worth $5,369,000 after acquiring an additional 634 shares during the period. Stonegate Investment Group LLC boosted its position in shares of Johnson & Johnson by 0.5% during the 1st quarter. Stonegate Investment Group LLC now owns 537,343 shares of the company's stock valued at $89,113,000 after acquiring an additional 2,448 shares in the last quarter. Finally, Worth Financial Advisory Group LLC bought a new stake in Johnson & Johnson in the first quarter valued at about $210,000. 69.55% of the stock is owned by institutional investors.
Analyst Ratings Changes
A number of equities research analysts have weighed in on JNJ shares. Barclays decreased their price objective on Johnson & Johnson from $166.00 to $165.00 and set an "equal weight" rating on the stock in a report on Thursday, April 17th. Sanford C. Bernstein reiterated a "market perform" rating on shares of Johnson & Johnson in a research report on Wednesday, April 16th. Guggenheim reissued a "neutral" rating on shares of Johnson & Johnson in a report on Wednesday, April 2nd. Morgan Stanley upped their target price on shares of Johnson & Johnson from $164.00 to $169.00 and gave the stock an "equal weight" rating in a report on Wednesday, April 16th. Finally, Royal Bank Of Canada restated an "outperform" rating and issued a $181.00 price target on shares of Johnson & Johnson in a research report on Thursday, June 5th. Eleven research analysts have rated the stock with a hold rating, seven have assigned a buy rating and three have assigned a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $170.88.
View Our Latest Analysis on JNJ
Johnson & Johnson Stock Up 0.6%
Shares of JNJ stock traded up $0.95 during trading hours on Tuesday, hitting $152.27. 9,539,679 shares of the company were exchanged, compared to its average volume of 8,001,956. The company has a market capitalization of $366.36 billion, a PE ratio of 16.94, a PEG ratio of 2.29 and a beta of 0.42. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $169.99. The business has a 50 day moving average of $154.01 and a two-hundred day moving average of $153.69. The company has a current ratio of 1.26, a quick ratio of 1.03 and a debt-to-equity ratio of 0.49.
Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings data on Tuesday, April 15th. The company reported $2.77 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.59 by $0.18. Johnson & Johnson had a return on equity of 33.46% and a net margin of 24.42%. The business had revenue of $21.89 billion during the quarter, compared to the consensus estimate of $21.65 billion. Analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.
Johnson & Johnson Increases Dividend
The firm also recently declared a quarterly dividend, which was paid on Tuesday, June 10th. Shareholders of record on Tuesday, May 27th were given a dividend of $1.30 per share. The ex-dividend date was Tuesday, May 27th. This is a boost from Johnson & Johnson's previous quarterly dividend of $1.24. This represents a $5.20 annualized dividend and a yield of 3.42%. Johnson & Johnson's payout ratio is 57.84%.
About Johnson & Johnson
(
Free Report)
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.
Recommended Stories
Before you consider Johnson & Johnson, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson & Johnson wasn't on the list.
While Johnson & Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
